S&P Futures
4,162.50 -13.25 (-0.32%) Dow Futures
34,111.00 -95.00 (-0.28%) Nasdaq Futures
12,738.75 -38.00 (-0.30%) Russell 2000 Futures
1,970.00 -9.30 (-0.47%) Crude Oil
77.94 +0.80 (+1.04%) Gold
1,894.90 +10.10 (+0.54%)
Chart Events
Performance Outlook
| Previous Close | 1.9750 |
| Open | 2.0000 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 900 |
| Day's Range | 1.9800 - 2.1000 |
| 52 Week Range | 1.0000 - 11.1840 |
| Volume | |
| Avg. Volume | 6,157 |
| Market Cap | 3.813M |
| Beta (5Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3270 |
| Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small
- GlobeNewswire
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update
- GlobeNewswire
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmace
